Healthcare / BiotechnologyShanghai
$36.06
+0.59 (+1.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $925474.13 · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
78.4x
↑EV/EBITDA
46.2x
↑ROE
4.7%
↑Gross Margin
78.1%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.0%
FCF CAGR
-71.8%
FCF margin
0.5%
FCF / Net income
0.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $196.2M · net income $51.8M · FCF $925474.1
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $196.2M | $196.2M | $194.9M | $190.1M | $174.2M |
| Net Income | $51.8M | $51.8M | $44.3M | $38.8M | $64.2M |
| EBITDA | $83.7M | $83.7M | $71.1M | $63.2M | $89.6M |
| EPS | 0.48 | 0.48 | 0.41 | 0.36 | 0.63 |
| Gross Margin | 78.1% | 78.1% | 78.1% | 75.7% | 83.8% |
| Operating Margin | 28.0% | 28.0% | 27.4% | 20.0% | 34.8% |
| Net Margin | 26.4% | 26.4% | 22.7% | 20.4% | 36.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Current Ratio | 26.39 | 26.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $925474.13 | $925474.13 | $-9.1M | $4.1M | $41.5M |
| Returns | |||||
| ROE | 4.7% | 4.7% | 4.0% | 3.6% | 5.7% |
| Valuation | |||||
| P/E | 78.39 | 78.39 | 41.17 | 55.08 | 35.25 |
| EV/EBITDA | 46.16 | 46.16 | 23.15 | 31.60 | 19.65 |
| P/B | 3.50 | 3.50 | 1.66 | 1.97 | 2.02 |
| Growth & Yield | |||||
| Revenue Growth | 0.7% | 0.7% | 2.5% | 9.1% | — |
| EPS Growth | 17.1% | 17.1% | 13.9% | -42.9% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
88.2%
EPS terminal req.
$3.20
Spread vs growth
-71.1%
5Y implied EPS CAGR
51.8%
EPS terminal req.
$3.87
Spread vs growth
-34.7%
10Y implied EPS CAGR
29.2%
EPS terminal req.
$6.24
Spread vs growth
-12.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+98.9%
Start / end P/E
44.5x → 75.1x
EPS bridge
0.41 → 0.48
Residual
+11.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.